Cell free fetal DNA to triage antenatal rhesus immune globulin: Is it really cost-effective in the United States?

Kenneth Jpseph MoiseSyed Shahrukh HashmiKara MarkhamPedro S ArgotiMichael Bebbington

Published in: Prenatal diagnosis (2019)

The use of cfDNA to determine the selective use of antenatal RhIG would not be cost-effective in the United States. Universal antenatal RhIG without paternity is more effective in preventing new cases of alloimmunization than the current ACOG guideline.

Keyphrases

cell free
pregnant women
circulating tumor
preterm birth
emergency department
sickle cell disease
circulating tumor cells